Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management

Endocrinology. 2022 Apr 1;163(4):bqac027. doi: 10.1210/endocr/bqac027.

Abstract

Ductal carcinoma in situ (DCIS) makes up a majority of noninvasive breast cancer cases. DCIS is a neoplastic proliferation of epithelial cells within the ductal structure of the breast. Currently, there is little known about the progression of DCIS to invasive ductal carcinoma (IDC), or the molecular etiology behind each DCIS lesion or grade. The DCIS lesions can be heterogeneous in morphology, genetics, cellular biology, and clinical behavior, posing challenges to our understanding of the molecular mechanisms by which approximately half of all DCIS lesions progress to an invasive status. New strategies that pinpoint molecular mechanisms are necessary to overcome this gap in understanding, which is a barrier to more targeted therapy. In this review, we will discuss the etiological factors associated with DCIS, as well as the complexity of each nuclear grade lesion. Moreover, we will discuss the possible molecular features that lead to progression of DCIS to IDC. We will highlight current therapeutic management and areas for improvement.

Keywords: breast cancer; ductal carcinoma in situ; invasive breast cancer; invasive ductal carcinoma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / therapy
  • Carcinoma, Ductal, Breast* / pathology
  • Carcinoma, Intraductal, Noninfiltrating* / genetics
  • Carcinoma, Intraductal, Noninfiltrating* / therapy
  • Female
  • Humans